Ken Herrmann

Nuc Med - Theranostics - Innovation. Embracing Change.

[JNM @JournalofNucMed]

Temporal ¹⁸F-PI-2620 binding is associated with genetic Alzheimer’s disease risk, plasma p-tau₂₁₇, female sex, and episodic memory deficits in cognitively unimpaired. older adults. https://t.co/DqWs3zkrAX

#NuclearMedicine #PETscan

[Michael Hofman @DrMHofman]

Dive into a Total Body PET @JournalofNucMed podcast with my heroes of nuclear medicine - Prof Simon Cherry, @stefanofanti4 and @ProfKHerrmann

https://t.co/3B8QvCCkeA

[OncoDaily @oncodaily]

Total-Body PET Advances Precision Imaging and Early Cancer Detection - Ken Herrmann

@ProfKHerrmann @JournalofNucMed @DrMHofman

https://t.co/kYYEsN5wE5

[JNM @JournalofNucMed]

Sub–0.5-mm resolution allows the HR-PET to provide ¹⁸F-FITM uptake images of the mouse brain similar to those of the autoradiography, opening up new research opportunities for neurodegenerative diseases in mouse models. https://t.co/lmAobz53Td

#NuclearMedicine

[UroToday.com @urotoday]

Understanding #RadiopharmaceuticalTherapy in #ProstateCancer: From Mechanism to Clinical Practice.
Radiopharmaceutical therapy is rapidly reshaping the treatment landscape in advanced prostate cancer, bringing new opportunities—and new clinical questions—around patient selection, treatment sequencing, safety, mechanism of action, and future integration.

In this exclusive UroToday clinical conversation series, leading experts in #MedicalOncology, #RadiationOncology, #NuclearMedicine, and TranslationalScience explore the evolving role of radiopharmaceutical therapy across the prostate cancer continuum. Through practical, peer-to-peer discussions, this series examines today’s treatment landscape, the biological and mechanistic distinctions between emerging approaches, real-world considerations for clinical decision-making, and where the next wave of innovation may take the field.
#WatchNow > https://t.co/1TxxOAYVcG #MichaelMorris @DrRanaMcKay @ProfKHerrmann @PrafulRavi1 @boothe_dustin @PhillipKooMD @nhbander @TDorffOnc @DrPhilKantoff @ConvergentRx #NealShore

[Toni Choueiri, MD @DrChoueiri]

….So it begins!

#ASCO26 #belong

[Toni Choueiri, MD @DrChoueiri]

The⚽️tournament @ASCO is back:

Registration is open--see below with @cdanicas for all what you need to know! #ASCO25 @OncoAlert @FAndreMD @jrgralow

[Weijun Wei @Weijun_Wei89]

Seeing is believing. CcRCC has the most complex metastatic patterns and many patients are misdiagnosed in routine clinical practice. CD70 PET is changing the landscape in China, many patients benefit from the imaging clinical trials. Need to develop CD70 therapeutic drugs!

[Michael Hofman @DrMHofman]

First images from the GE Omni 128 cm Total Body PET/CT 🚀

The new scanner detected a <5 mm local recurrence of prostate cancer missed by standard PSMA PET/CT - despite 79% shorter acquisition ⏱️

Delayed imaging boosted lesion uptake and informed dose-painted salvage RT 🎯

@JournalofNucMed @PeterMacCC @declangmurphy @_ShankarSiva
https://t.co/Kiq9PHC12X

[OncoAlert @OncoAlert]

As if we needed another reason to go to #APCCC26 and #IPCS26 🇨🇭
A warm welcome to the #APCCC5k , a great way to start the day with a fun Run/Walk around Lake Lugano Switzerland. More details once you get to Lugano, but just reminding our colleagues...Bring your Running shoes, we will :-) See you There!!

@Silke_Gillessen & @AOmlin

@fabioturco92
@Prof_IanD
@drjefstathiou
@Prof_Nick_James
@ChrisSweens1
@BertrandTOMBAL
@ZilliThomas
@neerajaiims
@bjartell
@PBlanchardMD
@BourlonMaite
@Albert0Briganti
@cdanicas
@Ecastromarcos
@mdesantis234
@nachoduranm
@drlouiseemmett
@stefanofanti4
@fontev1
@Nicola_Fossati
@marty_gleave
@ProfKHerrmann
@DrMHofman
@BarbaraJereczek
@ravikanesvaran
@FacsRaja
@LoebStacy
@quimmateo
@DrRanaMcKay
@amerseburger
@CaPsurvivorship
@declangmurphy
@DrPaulNguyen
@WilliamOhMD
@piet_ost
@DrSpratticus
@cnsternberg
@DrYukselUrun
@UrsulaVogl

Ping
@nataliagandur
@OncoAlert 🚨

[JNM @JournalofNucMed]

First total-body kinetics study of ¹⁸F-flurpiridaz in healthy volunteers at rest and feasibility of simplified quantitative strategies. https://t.co/Vi2YOtKoN6

#NuclearMedicine #PETscan #MolecularImaging

[OncoAlert @OncoAlert]

A reminder that #APCCC26 🇨🇭is coming in Late April and is OPEN TO EVERYONE, not just the Panel members and 👉️ REGISTER HERE: https://t.co/1qjFJdCJ3P

🚨 Enjoy 20% off when registering for both APCCC & IPCS 2026

Awarm invite to the Advanced Prostate Cancer Consensus Conference #APCCC26 in Lugano🇨🇭

Event Details:
📍 Palazzo Congressi, Lugano, Switzerland
🎟️ Register here
🎓 Credits requests: SGU – SSU, SSMO, SRO, SGMN

In an era of rapid innovation and expanding treatment options for advanced #ProstateCancer , APCCC provides a vital forum for clinicians and researchers to address complex clinical questions where high-level evidence is limited. Over two days, the world’s leading experts will engage in high-level presentations, debates, and discussions to clarify and conceptualize the current landscape of care, with a focus on areas of controversy or uncertainty. The insights and consensus developed during the meeting are later published in European Urology, helping shape global standards.

Creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer!

@Silke_Gillessen & @AOmlin

@fabioturco92
@Prof_IanD
@drjefstathiou
@Prof_Nick_James
@ChrisSweens1
@BertrandTOMBAL
@ZilliThomas
@neerajaiims
@bjartell
@PBlanchardMD
@BourlonMaite
@Albert0Briganti
@cdanicas
@Ecastromarcos
@mdesantis234
@nachoduranm
@drlouiseemmett
@stefanofanti4
@fontev1
@Nicola_Fossati
@marty_gleave
@ProfKHerrmann
@DrMHofman
@BarbaraJereczek
@ravikanesvaran
@FacsRaja
@LoebStacy
@quimmateo
@DrRanaMcKay
@amerseburger
@CaPsurvivorship
@declangmurphy
@DrPaulNguyen
@WilliamOhMD
@piet_ost
@DrSpratticus
@cnsternberg
@DrYukselUrun

Ping
@nataliagandur
@OncoAlert 🚨

[Michael Hofman @DrMHofman]

PCWG4 is launched: https://t.co/0IA8ltzxlG

Imaging response is expanded to include PSMA PET/CT.

In the future, patient may have 1 scan (PSMA PET with CT) rather than two scans (CT+ bone scan). All my nuclear colleagues will be happy to retire the bone scan.

@AarmstrongDuke

[OncoAlert @OncoAlert]

The #OncoAlertTopTweet 🚨DAY ONE #GU26
Post: OncoAlert

Just Published at @JCO_ASCO and out for #GU26

ABSTRACT 162 Poster Bd E17
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4

👉https://t.co/aUwlyQoBo2 Here is Dr Michael Morris🇺🇸from @MSKCancerCenter
to tell us more #ProstateCancer

@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin

@DrRanaMcKay
Michael J. Morris
@EAntonarakis
@mishabeltran
@drlouiseemmett
@ProfKHerrmann
@DrMHofman
@JoshLangMD
@CaPsurvivorship
@Cpaller
@cnsternberg

[OncoAlert @OncoAlert]

The #OncoAlertTopTweet 🚨DAY ONE #GU26
Post: OncoAlert 🌐

Just Published at @JCO_ASCO and out for #GU26

Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4

👉https://t.co/aUwlyQoBo2

Here is Dr Andrew Armstrong🇺🇸 @AarmstrongDuke to tell us more #ProstateCancer

@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin

@DrRanaMcKay
Michael J. Morris
@EAntonarakis
@mishabeltran
@drlouiseemmett
@ProfKHerrmann
@DrMHofman
@JoshLangMD
@CaPsurvivorship
@Cpaller
@cnsternberg

[OncoAlert @OncoAlert]

The #OncoAlertTopTweet 🚨DAY ONE #GU26

#APCCC26 🇨🇭 is open to everyone (not just panel members!) and is on April 30-May 2nd in Lugano
EARLY REGISTRATION CLOSES February 28, 2026
👉 REGISTER HERE: https://t.co/1qjFJdDgTn

Join global experts in advanced #ProstateCancer at the Advanced Prostate Cancer Consensus Conference in Lugano (Palazzo Congressi) for two days of high-level debates addressing real-world clinical questions where evidence is limited, shaping future standards of care published in European Urology while creating opportunities for the next generation of leaders; enjoy 20% off when registering for both APCCC & IPCS 2026

@Silke_Gillessen @AOmlin @fabioturco92 @Prof_IanD @drjefstathiou @Prof_Nick_James @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti @cdanicas @Ecastromarcos @mdesantis234 @nachoduranm @drlouiseemmett @stefanofanti4 @fontev1 @Nicola_Fossati @marty_gleave @ProfKHerrmann @DrMHofman @BarbaraJereczek @ravikanesvaran @FacsRaja @LoebStacy @quimmateo @DrRanaMcKay @amerseburger @CaPsurvivorship @declangmurphy @DrPaulNguyen @WilliamOhMD @piet_ost @DrSpratticus @cnsternberg @DrYukselUrunPing @nataliagandur @OncoAlert

[JNM @JournalofNucMed]

Pretherapy ¹²⁴I PET/CT dosimetry shows that metastatic lesions absorb higher radiation doses after thyroid hormone withdrawal than after recombinant human TSH injection. https://t.co/EZmgHnyZx7

#NuclearMedicine #ThyroidCancer #PETscan @ProfKHerrmann

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

177Lu-PSMA-617 Monotherapy Is Provocative but No Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer

https://t.co/QCaSiuEfvG

This invited perspective discusses a patient with low-volume metastatic hormone-sensitive #ProstateCancer who declined standard ADT-based therapies and instead received first-line off-label Lu-PSMA monotherapy, achieving a partial response with minimal toxicity.

Although the case is intriguing and reflects growing interest in earlier PSMA-targeted treatment, the authors stress that it represents a single, highly selected patient and does not outweigh strong evidence supporting ADT-based doublet or triplet regimens as the proven standard of care.

They highlight key limitations—modest PSA response, short follow-up, uncertain generalizability, mechanistic uncertainties, and ethical concerns about off-label use—and emphasize that Lu-PSMA monotherapy should not be used outside clinical trials. Overall, while patients may wish to avoid ADT side effects, there is no evidence that ADT-free strategies preserve survival, and prospective studies are essential before altering current practice.

@ProfHadaschik
@Silke_Gillessen
Oliver Sartor

@OncoAlert 🚨
@AOmlin
@weoncologists

[Michael Hofman @DrMHofman]

First in the world @GEHealthCare Omni 128cm Total Body PET just installed at @PeterMacCC ... serial number 001.

50 times the sensitivity of our existing PET scanner enabling faster scanning with less radiation and greater clarity.

Our new centre seamlessly integrates pre-clinical imaging, state-of-the-art radiopharmaceutical sciences to enable rapid translation from laboratory to clinic.

Thank-you to @ACRF_ @NIFAus @UniMelb

[ESMO - Eur. Oncology @myESMO]

Are you ready for radioligand therapy? Join the next #ESMOOnAir webinar part of the Therapeutic Landscapes series:
- Science, clinical trials &amp; system readiness for RLT
- Live expert Q&amp;A

🔗 https://t.co/JBClVPWTAa

#Oncology #Radiotheranostics #CancerCare #RLT #MedicalEducation